ClinicalTrials.gg
CompletedNCT07281937EVOLVE-2Updated Aug 17, 2026

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Phase 2 interventional study of VRB-101 and Placebo in Obesity and Overweight, sponsored by Verdiva Bio Dev Limited. Completed at 22 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Verdiva Bio Dev Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study of oral ecnoglutide (VRB-101), with 5 active arms and 1 placebo arm. The study will include a Screening Period of 4 weeks, followed by a 20-week Study Treatment Period and a 4-week Safety Follow-up Period prior to the end of study (EOS) visit.

02

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Hypertension
  • Weight reduction
  • Dose Escalation
  • Glucagon-like peptide-1 (GLP-1)
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 206 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Verdiva Bio Dev Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have (HbA1c) \<6.5%.
  • Have a of ≥30 kg/m2 OR ≥27 kg/m2 and \<30 kg/m2 with at least 1 weight-related comorbidity.
  • Have a self-reported history of stable body weight for the 3 months prior to randomization (≤5% body weight change).
  • Participants of must be non-pregnant and non-lactating and must agree to use study-specified methods.

Exclusion criteria

Exclusion Criteria:

  • Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or other forms of diabetes mellitus. A participant with a history of gestational diabetes may be included in the study if the participant has an \< 6.5% at Screening.
  • Have at least 1 laboratory value suggestive of diabetes during Screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L).
  • Have had exposure to glucagon-like peptide -1 (GLP-1) 6 months prior to Screening or any prior history of known or suspected /allergies, intolerability, or lack of efficacy to these medications. Have known or suspected hypersensitivity to study intervention(s), to selective GLP-1 receptor agonist (RA) or glucose-dependent insulinotropic peptide (GIP)/GLP-1 or GLP-1/glucagon (GCG) dual receptor agonists.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time within the dosing period, including follow -up, and for at least 60 days after the last dose of study intervention.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Schedule A: VRB-101 (Active Arm 1)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    Schedule A: VRB-101 (Active Arm 2)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    Schedule A: VRB-101 (Active Arm 3)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    Schedule B: VRB-101 (Active Arm 4)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    Schedule B: VRB-101 (Active Arm 5)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Placebo comparator
    Pooled Placebo

    Participants will receive matching placebo to VRB-101 once every week.

    Drug: Placebo

Interventions

  • DrugVRB-101

    VRB-101 tablets will be administered orally.

    Also known as: Oral Ecnoglutide

  • DrugPlacebo

    Placebo tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. Mean percent change from baseline in body weight

    To evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in Schedule A dose regimens.

    Time frame: From Baseline (Day 0) up to Week 21

Secondary outcomes

  1. Absolute change from baseline in body weight

    To compare the effect of VRB-101 versus placebo on body weight in Schedule A.

    Time frame: From Baseline (Day 0) up to Week 21

  2. Percentage of participants who achieve 5% or more body weight reduction

    To compare the effect of VRB-101 versus placebo on body weight in Schedule A

    Time frame: From Baseline (Day 0) up to Week 21

  3. Change from baseline in body mass index (BMI)

    To compare the effect of VRB-101 versus placebo on body weight in Schedule A.

    Time frame: From Baseline (Day 0) up to Week 21

  4. Number of study participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    To assess safety and tolerability of study interventions. Adverse events (AEs) reported after first administration of study intervention will be designated as a TEAE.

    Time frame: From Baseline (Day 0) up to Week 24

  5. Change from baseline in blood pressure (BP)

    To assess safety and tolerability of study interventions.

    Time frame: From Baseline (Day 0) up to Week 24

  6. Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS systematically assesses suicidal ideation and behavior using yes/no questions, ordinal severity ratings (0-5), and intensity subscales. Results at End of Study will be compared to Baseline.

    Time frame: From Baseline (Day 0) up to Week 21

07

Study locations

22 sites
  • Clinical Study Site 103
    Anniston, Alabama 36207, United States
  • Clinical Study Site 109
    Cullman, Alabama 35055, United States
  • Clinical Study Site 110
    Phoenix, Arizona 85028, United States
  • Clinical Study Site 113
    Little Rock, Arkansas 72205, United States
  • Clinical Study Site 111
    Anaheim, California 92801, United States
  • Clinical Study Site 107
    Montclair, California 91763, United States
  • Clinical Study Site 118
    Tarzana, California 91356, United States
  • Clinical Study Site 119
    Decatur, Georgia 30030, United States
  • Clinical Study Site 116
    West Des Moines, Iowa 50266, United States
  • Clinical Study Site 106
    Wichita, Kansas 67207, United States
  • Clinical Study Site 122
    Southfield, Michigan 48076, United States
  • Clinical Study Site 121
    Omaha, Nebraska 68134, United States
  • Clinical Study Site 117
    Binghamton, New York 13905, United States
  • Clinical Study Site 101
    Rochester, New York 14609, United States
  • Clinical Study Site 120
    Charlotte, North Carolina 28210, United States
  • Clinical Study Site 108
    Monroe, North Carolina 28112, United States
  • Clinical Study Site 105
    Norman, Oklahoma 73069, United States
  • Clinical Study Site 114
    Duncansville, Pennsylvania 16635, United States
  • Clinical Study Site 115
    Knoxville, Tennessee 37909, United States
  • Clinical Study Site 112
    Dallas, Texas 75251, United States
  • Clinical Study Site 102
    San Antonio, Texas 78229, United States
  • Clinical Study Site 104
    San Antonio, Texas 78240, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jul 2026, 7 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 15, 2025
StartActual
Nov 25, 2025
Primary completionActual
Jul 23, 2026
CompletionActual
Jul 23, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07281937
Lead sponsor
Verdiva Bio Dev Limited
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Nov 25, 2025
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026
Last update
Aug 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion